Physician profile
Chad E Renner
NPI 1841351426
$1,929.60
in general payments reported to CMS, 2019-2025
10 companies · $786 in 2025
The $786 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.56 · 2020: $90.46 · 2021: $202 · 2022: $402 · 2023: $237 · 2024: $131 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $426.43 | 2021-2024 | |
| Alcon Vision LLC | $397.56 | 2019-2025 | Precision7 |
| Johnson & Johnson Vision Care, INC. | $345.26 | 2019-2025 | Acuvue |
| Coopervision INC. | $248.98 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Sun Pharmaceutical Industries INC. | $115.59 | 2025 | |
| Allergan, INC. | $114.59 | 2022 | |
| Lkc Technologies, INC. | $113.75 | 2025 | |
| Abbvie INC. | $100.37 | 2022 | |
| Glaukos Corporation | $53.19 | 2020 | |
| Alcon Research LLC | $13.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Renner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.